0000000000154449

AUTHOR

Angelo Cattaneo

showing 2 related works from this author

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct